Loading
For very expensive one-time treatments such as CAR-T, pay in instalments over years and stop paying if the cancer comes back, so price tracks the cure actually delivered.
One-time curative-intent therapies (CAR-T, gene therapies, potentially in vivo cell therapy) carry prices that health systems struggle to absorb up front and that are not tied to durability. Outcome-based agreements exist in a few countries. The proposal is a standard contract framework: payments spread over five years, annual instalments contingent on registry-verified remission, portability across payers when patients move, and public reporting of durability, with the same framework offered in middle-income countries at tiered prices.
Shares Ciltacabtagene autoleucel, Axicabtagene ciloleucel, Prices and value, CAR-T cell therapy.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Incentives reward me-too drugs and marginal gains, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value, CAR-T cell therapy.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Incentives reward me-too drugs and marginal gains, Prices and value.
Shares Ciltacabtagene autoleucel, Axicabtagene ciloleucel, CAR-T cell therapy.
Shares Ciltacabtagene autoleucel, Axicabtagene ciloleucel, Incentives reward me-too drugs and marginal gains, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value, CAR-T cell therapy.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.